FibroGen names appointment for newly created Chief Scientific Officer role
FibroGen has created the new role of Chief Scientific Officer and appointed Dr Percy Carter to the position, it has emerged.
Dr Carter joins the company from Janssen, where he led over 700 employees as Global Head of Discovery Sciences in functions including Computational Sciences, Discovery Chemistry, Drug Metabolism & Pharmacokinetics, Lead Discovery, and Core Business Services. During this time, he primarily led operations to identify and refine novel small molecule, peptide, and RNA-based drug candidates.
Prior to his time at Janssen, he also served for almost two decades at Bristol-Myers Squibb, where he most recently served as Senior Vice President and Head of Discovery. He joined the company when it acquired DuPont Pharmaceuticals in 2001, having started his first major role as a Senior Research Scientist in Chemical and Physical Sciences.
“Great science and innovation are the backbone of FibroGen and what enable us to develop transformational medicines for patients. With Percy’s leadership, we will continue our legacy of biological breakthroughs and advancing first-in-class therapeutics,” remarked FibroGen Chief Executive Officer Enrique Conterno. “Percy’s expertise and experience make him the ideal person to lead FibroGen’s scientific agenda. I look forward to his leadership impact on advancing our unique position in both hypoxia-inducible factor and connective tissue growth factor biology to expand our pipeline of novel drug candidates.”
Aside from his professional career in life sciences, Dr Carter is listed as an inventor or co-inventor on 28 US patents and has authored or co-authored 85 peer-reviewed publications.
Japan approves Astellas and FibroGen’s Evrenzo for chronic kidney disease patients currently not receiving dialysis
Japan’s Ministry of Health, Labour and Welfare (MHLW) has passed approval for Astellas and FibroGen’s …
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …